PEmbrolizumab, Maveropepimut-S, and low-dose Cyclophosphamide in advanced epithelial Ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial

ASCO, JUNE 2022

PEmbrolizumab, Maveropepimut-S, and low-dose Cyclophosphamide in advanced epithelial Ovarian cancer: Results from phase 1 and expansion cohort of PESCO trial
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC)

ASCO, June 2022

Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor positive (HR+) early-stage breast cancer (ESBC)
Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy

IMMUNOLOGY 2022, May 2022

Proteomic analysis of plasma exosomes as biomarkers of response to MVP-S based immunotherapy
Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer

AACR, APRIL 2022

Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer
NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy

AACR, APRIL 2022

NK cells are involved in promoting anti-tumor responses to DPX-peptide immunotherapy

Translational analyses of the DeCidE1clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment

ESMO-IO, DECEMBER 2021

Translational analyses of the DeCidE1clinical study in advanced ovarian cancer patients reveal a substantial role for B cells in the clinical benefit derived from maveropepimut-S (MVP-S) treatment
Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer

SITC, November 2021

Identification of potential response predictors to maveropepimut-S (DPX-Survivac), a novel T cell activating immunotherapy, in patients with advanced recurrent ovarian cancer
DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model

AACR-NCI-EORTC, October 2021

DPX-SurMAGE, a novel dual-targeted immunotherapy for bladder cancer, induces target-specific T cells with a favorable safety profile in preclinical model
Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

AACR-NCI-EORTC, October 2021

Survivin peptides formulated in the DPX delivery platform rather than standard emulsions, elicit a robust, sustained T cell response to survivin in advanced and recurrent ovarian cancer patients

Scientific Reports, February 2021

Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

Brennan S. Dirk, Genevieve Weir, Tara Quinton, Olga Hrytsenko, Marianne M. Stanford